Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?

Journal of the American Academy of Dermatology

Volumn 62, Issue 2, 2010, Pages 337-342

  Boyd, Alan S ^a   Sanyal, Soma ^b   Abraham, Jerrold L ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

gadolinium; leg ulcer; nephrogenic systemic fibrosis

Indexed keywords

CALCIUM ACETATE; CYCLOSPORIN; GADODIAMIDE; LAMIVUDINE; NIFEDIPINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PREDNISONE; PSEUDOMONIC ACID; RAMIPRIL; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG ACCUMULATION; DRUG TISSUE LEVEL; GRAFT RECIPIENT; HEMODIALYSIS PATIENT; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; LEG ULCER; LIVER FAILURE; LIVER TRANSPLANTATION; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; PRIORITY JOURNAL; RASH; ROENTGEN SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; SKIN BIOPSY; SKIN FIBROSIS;

CONTRAST MEDIA; GADOLINIUM; GADOLINIUM DTPA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LIVER TRANSPLANTATION; MALE; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; RENAL DIALYSIS;

EID: 73649106155     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.04.010     Document Type: Article

References (44)

1. Cowper S.E., Robin H.S., Steinberg S.M., Su L.D., Gupta S., and LeBoit P.E. Scleromyxedema-like cutaneous diseases in renal-dialysis patients. Lancet 356 (2000) 1000-1001
2. Cowper S.E., Su L.D., Bhawan J., Robin H.S., and LeBoit P.E. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23 (2001) 383-391
3. Ting W.W., Stone M.S., Madison K.C., and Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139 (2003) 903-909
4. Cowper S.E., Bucala R., and LeBoit P.E. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis-setting the record straight. Semin Arthritis Rheum 35 (2005) 208-210
5. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104-1108
6. Marckmann P., Skov L., Rossen K., Dupont A., Damholt M.B., Heaf J.G., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 (2006) 2359-2362
7. Shabana W.M., Cohen R.H., Ellis J.H., Hussain H.K., Francis I.R., Su L.D., et al. Nephrogenic systemic fibrosis: a report of 29 cases. Am J Roentgenol 190 (2008) 736-741
8. Rydahl C., Thomsen H.S., and Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 43 (2008) 141-144
9. Marckmann P., Skov L., Rossen K., Heaf J.G., and Thomsen H.S. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 22 (2007) 3174-3178
10. Othersen J.B., Maize J.C., Woolson R.F., and Budisavljevic M.N. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 22 (2007) 3179-3185
11. Moreno-Romero J.A., Segura S., Mascaro J.M., Cowper S.E., Julia M., Poch E., et al. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible etiological factor. Br J Dermatol 157 (2007) 783-787
12. Lauenstein T.C., Salman K., Morreira R., Tata S., Tudorascu D., Baramidze G., et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging 26 (2007) 1198-1203
13. Todd D.J., Kaman A., Chibnik L.B., and Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 56 (2007) 3433-3441
14. Sieber M.A., Pietsch H., Walter J., Haider W., Frenzel T., and Weinmann H.J. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 43 (2008) 65-75
15. Boyd A.S., Zic J.A., and Abraham J.L. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56 (2007) 27-30
16. High W.A., Ayers R.A., Chandler J., Zito G., and Cowper S.E. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 (2007) 21-26
17. Boyd A.S., Sanyal S., and Abraham J.L. Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents. J Am Acad Dermatol 59 (2008) 356-358
18. Thakral C., and Abraham J.L. Automated scanning electron microscopy and x-ray microanalysis for in situ quantification of gadolinium deposits in skin. J Electron Microsc (Tokyo) 56 (2007) 181-187
19. Thakral C., Alhariri J., and Abraham J.L. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans; case report and implications. Contrast Media & Molecular Imaging 2 (2007) 199-205
20. Yerram P., Saab G., Karuparthi P.R., Hayden M.R., and Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure-role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2 (2007) 258-263
21. Kay J., and High W.A. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 58 (2008) 2543-2548
22. Abraham J.L., Thakral C., Skov L., Rossen K., and Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 158 (2008) 273-280
23. Lin S.P., and Brown J.J. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging 25 (2007) 884-899
24. Wahba I.M., Simpson E.L., and White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the literature. Am J Transplant 7 (2007) 2425-2432
25. Goveia M., Chan B.P., and Patel P.R. Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis. J Am Acad Dermatol 57 (2007) 725-727
26. Saab G. Epoetin and nephrogenic systemic fibrosis. J Am Acad Dermatol 58 (2008) 174-175
27. + cells with collagen synthesis activity in nephrogenic fibrosing dermopathy; a new pathogenic hypothesis. Br J Dermatol 150 (2004) 1050-1052
28. Bucala R. Circulating fibrocytes: cellular basis for NSF. J Am Coll Radiol 5 (2008) 36-39
29. Parsons A.C., Ysipovitch G., Sheehan D.J., Sangueza O.P., Greenberg C.S., and Sane D.C. Transglutaminases: the missing link in nephrogenic systemic fibrosis. Am J Dermatopathol 29 (2007) 433-436
30. Swartz R.D., Croford L.J., Phan S.H., Ike R.W., and Su L.D. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114 (2003) 563-572
31. Baron P.W., Cantos K., Hillebrand D.J., Hu K.Q., Okechukwu N.O., Nehlsen-Cannarella S., et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 25 (2003) 204-209
32. Maloo M., Abt P., Kashyap R., Younan D., Zand M., Orloff M., et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 6 (2006) 2212-2217
33. Caccetta T., and Chan J.J. Nephrogenic systemic fibrosis associated with liver transplantation, renal failure and gadolinium. Australas J Dermatol 49 (2008) 48-51
34. Hirano S., and Suzuki K.T. Exposure, metabolism and toxicity of rare earths and related compounds. Environ Health Perspect 104 Suppl (1996) 85-95
35. Abraham J.L., and Thakral C. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol 66 (2008) 200-207
36. White G.W., Gibby W.A., and Tweedle M.F. Comparison of Gd (DTPA-BMA) (Omniscan) versus Gd (HP-DO3A) (Prohance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 41 (2006) 272-278
37. Hansen R.M., Csuka M.E., McCarty D.J., and Saryan L.A. Gold induced aplastic anemia: complete response to corticosteroids, plasmapheresis, and N-acetylcysteine infusion. J Rheumatol 12 (1985) 794-797
38. Chu G., Mantin R., Shen Y.M., Baskett G., and Sussman H. Massive cisplatin overdose by accidental substitution for carboplatin: toxicity and management. Cancer 72 (1993) 3707-3714
39. Tian Y.R., Sun L.L., Wang W., Du F., Song A.X., Ni C.Y., et al. A case of acute thallotoxicosis successfully treated with double-filtration plasmapheresis. Clin Neuropharmacol 28 (2005) 292-294
40. Jhang J.S., Schilsky M.L., Lefkowitch J.H., and Schwartz J. Therapeutic plasmapheresis as a bridge to liver transplantation in fulminant Wilson disease. J Clin Apheresis 22 (2007) 10-14
41. Lewis K.G., Lester B.W., Pan T.D., and Robinson-Bostom L. Nephrogenic fibrosing dermopathy and calciphylaxis with pseudoxanthoma elasticum-like changes. J Cutan Pathol 33 (2006) 695-700
42. Guerra G., Shah R.C., and Ross E.A. Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous hemofiltration using low calcium replacement fluid: case report. Nephrol Dial Transplant 20 (2005) 1260-1262
43. Wiginton C.D., Kelly B., Oto A., Jesse M., Aristimuno P., Ernst R., et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. Am J Roentgenol 190 (2008) 1060-1068
44. Sadowski E.A., Bennett L.D., Chan M.R., Wentland A.L., Garrett A.L., Garrett R.W., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243 (2007) 148-157